MicroRNAs:非小细胞肺癌分子诊断和靶向治疗重要的靶标  

MicroRNAs:Key Target for Molecular Diagnosis and Treatment for Non-small Cell Lung Cancer

作　　者：李晓雅[1] 苏长青[1] 

机构地区：[1]第二军医大学东方肝胆外科医院,国家肝癌科学中心分子肿瘤研究室,上海200438

出　　处：《中国肿瘤》2014年第9期720-725,共6页China Cancer

基　　金：国家重大科技专项新药创制(2014ZX09101003);国家自然科学基金项目(81370552);上海市优秀学术带头人计划(13XD1400300)

摘　　要：microRNAs（miRNAs）是一类长度约为18~22个核苷酸、在动植物中广泛存在、高度保守的小分子非编码RNA。非小细胞肺癌（NSCLC）与其起源的相应正常细胞之间存在miRNAs表达谱的差异,不同类型或不同进展状态非小细胞肺癌之间miRNAs表达谱也有其特异性,为肺癌的早期诊断和鉴别诊断提供了候选指标。利用miRNAs调控靶基因表达的原理,还可以发现或设计更优化的肿瘤治疗模式。深入研究miRNAs在非小细胞肺癌中的作用和价值,将为筛选NSCLC分子诊断指标并据此建立靶向干预策略奠定基础。microRNAs（miRNAs） are small endogenous non-coding RNAs with length of 18~22 nucleotides which are widely existed and highly conservative in plants and animals. There are differences of miRNAs expression profiles between non-small cell lung cancer（NSCLC） and its originated normal cells. In different histological types or different development stages of NSCLC,there is also the existence of miRNAs expressing specificity,which provides the candidate tumor markers for early diagnosis and differentiated diagnosis of lung cancer. Based on the regulatory principle of miRNAs on target genes,the optimized strategy of cancer therapy may be discovered or designed.Further study on effect and value of miRNAs in NSCLC may lay the foundation for screening of NSCLC molecular diagnostic indices and accordingly establishment of targeted intervention strategy.

关 键 词：MICRORNAS 非小细胞肺癌 诊断 治疗 

分 类 号：R734.2[医药卫生—肿瘤]